Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome Strategies for In Vivo Administration: Part-II

Vista senzilla d'ítem
dc.contributor.authorVieira, Raquel
dc.contributor.authorSouto, Selma B.
dc.contributor.authorSánchez-López, E. (Elena)
dc.contributor.authorLópez-Machado, Ana
dc.contributor.authorSeverino, Patrícia
dc.contributor.authorJose, Sajan
dc.contributor.authorSantini, Antonello
dc.contributor.authorSilva, Amélia M.
dc.contributor.authorFortiuna, Ana
dc.contributor.authorGarcía López, María Luisa
dc.contributor.authorSouto, Eliana B.
dc.date.accessioned2020-06-19T14:59:30Z
dc.date.available2020-06-19T14:59:30Z
dc.date.issued2019-08-28
dc.date.updated2020-06-19T14:59:31Z
dc.description.abstractDiabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
dc.format.extent20 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec701303
dc.identifier.issn2077-0383
dc.identifier.pmid31466386
dc.identifier.urihttps://hdl.handle.net/2445/166339
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm8091332
dc.relation.ispartofJournal of Clinical Medicine, 2019, vol. 8, num. 9, p. 1332
dc.relation.urihttps://doi.org/10.3390/jcm8091332
dc.rightscc-by (c) Vieira, Raquel et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationDiabetis no-insulinodependent
dc.subject.classificationResistència a la insulina
dc.subject.classificationFarmacologia
dc.subject.classificationAnimals
dc.subject.otherNon-insulin-dependent diabetes
dc.subject.otherInsulin resistance
dc.subject.otherPharmacology
dc.subject.otherAnimals
dc.titleSugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome Strategies for In Vivo Administration: Part-II
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
701303.pdf
Mida:
653.74 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))